2D cell cultures have been the standard way to perform research in biologically related fields for over one hundred years. However, these simplified methods are time-consuming and lack physiological relevance. As a result, 3D cell cultures have increasingly gained ground as a means for performing experiments that are more translatable to human applications. Though more relevant, this kind of research is extremely time-consuming and limited by several manual procedures. In this presentation, I will introduce the BioBot: a bioprinter that allows for the automation of 3D biology, solving a wide range of problems. I will highlight the work that is being done with our printing platform in different labs around the world. One lab from the Harvard Medical School has used the Biobots platform to create a model of thrombosis on a chip in a faster and more realistic manner than with conventional methods. Another lab at the Wake Forest Institute for Regenerative Medicine has used the BioBots technology to create several “mini-tumors” from cancer patient tumor cells in order to personalize drugs for treatment. This kind of work, powered through the automation of 3D biology, gives great hope to not only create better, faster and more relevant experiments in bioengineering, but also to print organs and end the organ transplant waiting list. This is extremely important for countries like Brazil, whose public organ transplant system is the largest in the world.